New antifungal therapies for the treatment of onychomycosis

Expert Opinion on Investigational Drugs

Volumn 18, Issue 6, 2009, Pages 727-734

  Kumar, Sandeep ^b   Kimball, Alexa B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Onychomycosis; Systemic treatment; Topical treatment

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; 5 FLUORO 1,3 DIHYDRO 2,1 BENZOXABOROL 1 OL; ALBACONAZOLE; AMOROLFINE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BIFONAZOLE; CASPOFUNGIN; CICLOPIROX; CICLOPIROXOLAMINE; CICLOPOLI; CYTOCHROME P450 ISOENZYME; ECONAIL; ECONAZOLE; ERGOSTEROL; FLUCONAZOLE; HYPHANOX; IDP 108; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; MICAFUNGIN; NB 002; NM 100060; POSACONAZOLE; PRAMICONAZOLE; RAVUCONAZOLE; SORDARIN DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TERBINAFINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; APPLICATION SITE REACTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; IONTOPHORESIS; LOW LEVEL LASER THERAPY; MICROWAVE IRRADIATION; MINIMUM INHIBITORY CONCENTRATION; NANOEMULSION; ONYCHOMYCOSIS; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; REVIEW; TRANSUNGUAL LASER THERAPY; ULTRAVIOLET IRRADIATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DRUGS, INVESTIGATIONAL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MICROWAVES; ONYCHOMYCOSIS; PHOTOCHEMOTHERAPY; TRIAZOLES;

EID: 67649604197     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902810352     Document Type: Review

References (63)

1. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999;141(Suppl 56):1-4
2. Elewski BE. Onychomycosis: pathogenesis, diagnosis and management. Clin Microbiol Rev 1998;11:415-29
3. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43:244-8
4. Gupta AK, Jain HC, Lynde CW. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. Int J Dermatol 1997;36:783-7
5. Paus R, Peker S, Sundberg JP. Biology of hair and nails. second edition. In: Bolognia JL, editor. Dermatology. Amsterdam: Elsevier, 2008. p. 965-86
6. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007;20:31-46
7. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004;150:537-44
8. Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-7
9. Bräutigam M, Weidinger G, Nolting S. Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ 1998;317:1084
10. Zhang AY, Camp WL, Elewski BE. Advances in topical and systemic antifungals. Dermatol Clin 2007;25:165-83,vi
11. Barrier Therapeutics ends patient enrollment for Hyphanox. Available from: http://www.pharmaceutical-business-review.com/article-news.asp?guid= E30F7590-9F41-47C3-8383-42C18726711C [last accessed 12 March 2009]
12. Carrillo-Muñoz AJ, Giusiano G, Guarro J, et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents 2007;30:157-61. Epub 2007 Jun 6
13. Ghannoum M, Isham N. Antifungal activity of BAL 4815, a novel azole, against dermatophytes. 2nd Trends in Medical Mycology (TIMM), 23 - 26 October 2005, Berlin. Poster no. P-009
14. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
15. Available from: http://www.doctorfungus.org/thedrugs/Ravuconazole.htm [Last accessed 12 December 2008]
16. Gupta AK, Leonardi C, Stoltz RR, et al.; Ravuconazole onychomycosis group. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005;19:437-43
17. Piérard GE, Arrese JE, Quatresooz P, Piérard-Franchimont C. Emerging therapeutic agents for onychomycosis. Expert Opin Emerg Drugs 2007;12:345-53
18. Geria AN, Scheinfeld NS. Pramiconazole, a triazole compound for the treatment of fungal infections. IDrugs 2008;11:661-70
19. Scheinfeld N. A review of the new antifungals: posaconazole, micafungin, and anidulafungin. J Drugs Dermatol 2007;6:1249-51
20. ClinicalTrials.gov Identifier: NCT00491764
21. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
22. ClinicalTrials.gov Identifier: NCT00730405
23. Loo DS. Systemic antifungal agents: an update of established and new therapies. Adv Dermatol 2006;22:101-24
24. Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 2004;43(Suppl 1):3-8
25. Polak A. Mode of action of morpholine derivatives. Ann NY Acad Sci 1988;544:221-8
26. Ceschin-Roques CG, Hänel H, Pruja-Bougaret SM, et al. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. Skin Pharmacol 1991;4:89-94
27. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43(4 Suppl):S70-80
28. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005;19:21-9
29. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007;3:CD001434, doi:10.1002/14651858.CD001434.pub2
30. Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008;5:1267-82
31. Arpida reports progress in pivotal Phase III trial with TLT treatment in onychomycosis. Available from: http://www.arpida.ch/users/1/content/arpida-tlt- phiii.pdf [Last accessed 12 December 2008]
32. ClinicalTrials.gov Identifier: NCT00768768
33. Boker A, Bae YS, Gowrishankar TR, et al. A double-blind, placebo-controlled, pilot study of 1% terbinafine cream delivered via toenail microconduits for the treatment of subungual onychomycosis. Poster: 65th Annual Meeting of the American Academy of Dermatology, Washington DC, 2 - 6 February 2007
34. Available from: http://www.fiercebiotech.com/press-releases/nexmed- announces-decision nm100060[Last accessed 12 December 2008]
35. Iontophoretic application of terbinafine gel to the large toe nail. ClinicalTrials.gov NCT00459537
36. Bonifaz A, Guzmãn A, Garcia C, et al. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 1995;34:500-3
37. Torres-Rodríguez JM, Madrenys N, Nicolás MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses 1991;34:499-504
38. Roberts DT, Hay RJ, Doherty VR, et al. Topical treatment. of onychomycosis using bifonazole 1% urea/40% paste. Ann NY Acad Sci 1988;544:586-7
39. ClinicalTrials.gov Identifier: NCT00781820
40. ClinicalTrials.gov Identifier: NCT00385502
41. Available from: http://www.medicalnewstoday.com/articles/116086.php.
42. Jones T, Ijzerman, Flack M, Baker JR. Tolerability, safety and pharmacokinetics of topical nanoemulsion (NB-002) in patients with onychomycosis. Poster presented at Interscience conference on antimicrobial agents and chemotherapy, 17-20 Sept 2007, Chicago, IL, USA
43. ClinicalTrials.gov Identifier: NCT00453271
44. ClinicalTrials.gov Identifier: NCT00777868
45. Monti D, Saccomani L, Chetoni P, et al. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005;31:11-7
46. Barak O, Loo DS. AN-2690, a novel antifungal for the topical treatment of onychomycosis. Curr Opin Investig Drugs 2007;8:662-8
47. Mertin D, Lippold BC. In vitro permeability of the human nail and of a keratin membrane from bovine hooves: influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux. J Pharm Pharmacol 1997;49:30-4
48. Kobayashi Y, Komatsu T, Sumi M, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci 2004;21:471-7
49. Baker S, Sanders V, Hold K, Plattner J. In vitro nail penetration of AN2690, effect of vehicle, and coefficient of efficacy [abstract P1800]. J Am Acad Dermatol 2007;56(2):AB124
50. Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316:1759-61
51. AN2690. Available from: http://www.anacor.com/an2690.php [Last accessed 18 December 2008]
52. Alley MR, Baker SJ, Beutner KR, Plattner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 2007;16:157-67
53. Watanabe D, Kawamura C, Masuda Y, et al. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008;144:19-21
54. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008;59(5 Suppl):S75-6
55. Dai T, Tegos GP, Rolz-Cruz G, et al. Ultraviolet C inactivation of dermatophytes: implications for treatment of onychomycosis. Br J Dermatol 2008;158:1239-46
56. Microwave device offers tx without side effects, company says; Source: Special Report. Available from: http://mommd.mediwire.com/main/Default.aspx?P= Content&ArticleID=465499[Last accessed 6 February 2009]
57. Scher RK. Onychomycosis: therapeutic update. J Am Acad Dermatol 1999;40(Suppl):S21-6
58. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997;133:1172-3
59. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43:641-8
60. Anacor Phase 2 study of novel topical antifungal for onychomycosis demonstrates efficacy. Available from: http://www.medicalnewstoday.com/articles/ 52760.php [Last accessed 12 December 2008]
61. Warshaw EM. Evaluating costs for onychomycosis treatments: a practitioner's perspective. J Am Podiatr Med Assoc 2006;96:38-52
62. Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004;42:159-63
63. Ghannoum MA. Antifungal susceptibility-new developments. AAD 66th Annual Meeting. Forum 544 Mycology